NCT04865536View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 3, 2021

Primary Completion Date

May 17, 2021

Study Completion Date

May 17, 2022

Conditions
TuberculosisTuberculosis, Pulmonary
Interventions
DRUG

TBI-223 1800 mg

3 x 600 mg SR1 tablets

DRUG

TBI-223 2400mg

3 x 600 mg SR1 tablets and 1 x 600 mg IR tablets

DRUG

TBI-223 Placebo

Placebo SR and IR tablets for TBI-223

Trial Locations (1)

07410

TKL Research, Inc., Fair Lawn

All Listed Sponsors
lead

Global Alliance for TB Drug Development

OTHER

NCT04865536 - Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects | Biotech Hunter | Biotech Hunter